Sell Yourself

By DWIGHT NYBERG | President | MPA

In the early 1970’s, my Dad’s prescription volume was one-third of today’s volume, and he made twice the profit! That’s the new math I never understood.

The President’s call for zero copay on prescriptions for our Tricare patients is a prime example of not understanding healthcare. The lower copay for prescriptions should be available at the pharmacies that provide one-on-one or face-to-face consultation, patient education, drug therapy modification and/or product selection. The remaining pharmacies are mandated to charge copays.

It’s a proven fact that medication therapy management and patient education are both proactive methods of: Improving healthcare outcomes and quality of life. What an example of managing healthcare expenses! The same pharmacists who are hurt by this are already dispensing a larger percent of generic drugs. This helps the health care system save more money.

Could you do 20 or 30 MTM’s or patient education sessions each day, at $100 to $150 per session?

Remember, you’re the expert, you’re the best, you’re selling yourself.

Take a moment, estimate the dollar savings you could create each day, week, month, and year.

An easy $200 to $300 a day, $1,000 to $1,500 a week, $20,000 to $30,000 a month … you continue and use your estimate. Are you worth more than $150 per session?

Now, think about the diabetic, the asthma patient, the potential fall patient who’s lifestyle and quality of life you helped improve.

You’re the drug expert, you’re selling yourself !!!

Afraid the future will leave you behind? Then help create the future!

Participate with the Missouri Pharmacy Association as we challenge, change, and develop the future of Pharmacy.

An opportunity for all pharmacists!

Sell yourself, SELL YOURSELF!!!

Senate bill to encourage generic drug market

BY DIANE BARTZ | Washington | Reuters.com — Generic drugs would have an easier path to U.S. markets under a bill due to be introduced in the Senate, said Democratic Senator Jeff Bingaman, a sponsor of the bill.

The bill also has the support of Republican Senator David Vitter and will be introduced on Wednesday, Bingaman’s office said.

It would amend the 1984 Hatch-Waxman Act, which was supposed to empower generic drug companies by allowing them to challenge pharmaceutical patents if they thought they were weak.

If the generic company challenged a drug patent and won, it was rewarded with a 180-day window of exclusivity to sell a generic.

However, one result of that half-year of exclusivity is that brand-name and generic companies will settle a patent lawsuit but sometimes make a deal in which the generic company will stay out of the market for a period of time, according to critics of the practice.

Meanwhile, no other generic may come to market.

In some cases, the brand-name company paid the generic company to delay production, a type of deal the Federal Trade Commission calls “pay for delay.”

The Bingaman-Vitter bill would permit any generic company that successfully challenges a drug patent to enter the market, allowing more than one generic company to come to market.

To read the full article and many more like this, click here.